Heart Study Articles & Analysis
70 news found
Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass. Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of ...
Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass. Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available ...
Valo Health, Inc (“Valo”) shared the initial results of a collaborative study with the U.S. Food and Drug Administration (FDA), demonstrating the potential of Valo’s Biowire platform to predict clinical efficacy of Cardiac Contractility ...
DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking ...
(NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the results of four clinical studies presented at the American Heart Association’s (AHA) 2022 Scientific Sessions in Chicago, IL. ...
(NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced a new health economic analysis of the mSToPS study, presented at the American Heart Association’s 2022 Scientific Sessions event. The study, titled ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the prestigious Journal of Cardiac Failure demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF). ...
Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2022 – which brought together the world’s ...
Our BVA diagnostic is a non-invasive and inexpensive blood test which allows care teams to solve the significant challenge of accurately managing the fluid levels of patients, whether it is in the heart failure clinic or the hospitalized heart failure patient in the ICU. Studies published and presented are proving just how exciting the potential ...
The Company has conducted two proof-of-concept studies, the RED DESERT study in euvolemic heart failure patients and the SAHARA study in decompensated heart failure patients, demonstrating that intensive DSR therapy with DSR 1.0 delivers compelling and durable clinical improvements in diuretic-resistant ...
Mitochondrial DNA (mtDNA) plays an important role in the pathogenesis of the cardiovascular disease (CVD), especially in heart failure and ischemic heart disease. With the deepening of study, elevated evidence has suggested that mtDNA is regulated by the occurrence and development of CVD. ...
Non-invasive arrhythmia technology maps using only the data from a 12 lead ECG vMap provides actionable mapping results in minutes. Blinded, multi-center study with analysis by an independent core laboratory Results to be presented for the first time at Heart Rhythm 2022 Vektor Medical today announced positive results from its “Vektor ...
A sustained rapid heartbeat can also put stress on the heart and slow the movement of blood through the atria, increasing the risk of stroke, among other comorbidities2. ...
Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. Barostim works by stimulating baroreceptors - natural sensors in the body that tell the nervous system how to regulate heart, kidney and vascular function. These effects reduce the ...
ByCVRx
About the POSEIDON study POSEIDON is a single-arm, open-label and within subject cross-over study of the alfapump in patients with recurrent or refractory ascites due to liver cirrhosis and is being conducted in approximately 20 centres across the U.S. and Canada. ...
” "In addition to our critically important autologous cell therapies being studied for ischemic heart failure and chronic myocardial ischemia with refractory angina, the FDA's acceptance of this IND for patients recovering from ARDS is an important milestone in the development of our allogeneic mesenchymal stem cell therapy platform and validation for its ...
We are delighted to explore new indications and now start using PiCSO for inferior STEMI patients in the context of the PiCSO-AMI-V study,” says Prof. Carrié. The principal investigator of the study is Professor Adrian Banning, Oxford Heart Center, Oxford, UK. “We are pleased to be initiating the PiCSO-AMI-V ...
Institutional Review Board (IRB) approval has been granted and enrollment is underway for two studies of heart failure management (in-patient and outpatient) announced in May 2021 backed by landmark grants from the National Institutes of Health (NIH). Investigators at the Geisinger Medical system and investigators at the VA Hospital system are carrying out the ...
EchoPixel’s True3D software platform, a pre-operative planning technology that creates a hologram of the heart for study before an incision is ever made, has received PMDA Medical Device Registration and Approval in Japan. This first-of-its-kind software enables the entire heart surgical team to develop a precise personalized plan by ...